Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Long-Term Debt Repayments (2020 - 2026)

Aytu Biopharma has reported Long-Term Debt Repayments over the past 6 years, most recently at $465000.0 for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed 0.0% to $465000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 88.36% year-over-year, with the annual reading at $1.9 million for FY2025, 88.19% down from the prior year.
  • Long-Term Debt Repayments was $465000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $464000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $89.6 million in Q4 2021 and troughed at -$73.6 million in Q1 2022.
  • The 5-year median for Long-Term Debt Repayments is $268500.0 (2023), against an average of $2.5 million.
  • Year-over-year, Long-Term Debt Repayments skyrocketed 65306.57% in 2021 and then plummeted 577.64% in 2022.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $89.6 million in 2021, then tumbled by 100.03% to -$26000.0 in 2022, then skyrocketed by 188.46% to $23000.0 in 2023, then skyrocketed by 1921.74% to $465000.0 in 2024, then changed by 0.0% to $465000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Long-Term Debt Repayments are $465000.0 (Q4 2025), $464000.0 (Q3 2025), and $464000.0 (Q2 2025).